We have previously shown that avelumab can mediate ADCC in vitro using as targets a range of human tumor cell lines that express PD-L1, and that this lysis can be blocked using an anti-CD16 antibody to inhibit the interaction of CD16 on NK cells with the IgG1 Fc receptor on avelumab [3–5]. Here, FCGR3A is linked to neoplasm.